Gastroileostomy for controlling body weight and lipid profile: An experimental rat model

Keleidari, Behrouz; Mahmoudieh, Mohsen; Mofrad, Rastin Mohammadi; Shahabi, Shahab; Sheikhbahaei, Erfan

doi:10.1016/j.obmed.2019.100096

Cited by 2 publications

(4 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All of these features make it a good replacement for majority of drugs used postheart transplant care. Moreover, antiadhesion formation property and chemotherapy ability of Vitamin C adds credits to its therapeutic value as a prophylaxis against adhesion formation and malignant development postheart transplant 49–53 …”

Section: Discussionmentioning

confidence: 99%

“…Moreover, antiadhesion formation property and chemotherapy ability of Vitamin C adds credits to its therapeutic value as a prophylaxis against adhesion formation and malignant development postheart transplant. 49 , 50 , 51 , 52 , 53 …”

Section: Discussionmentioning

confidence: 99%

“…These adhesions can be a serious cause of CVA development 20,48 . Vitamin C has been shown to reduce postoperative adhesions formation significantly in rats' models 49,50 . This makes Vitamin C one among the antiadhesive agents.…”

Section: Htr Cav and Ascorbic Acid (Asc)mentioning

confidence: 99%

“… 20 , 48 Vitamin C has been shown to reduce postoperative adhesions formation significantly in rats' models. 49 , 50 This makes Vitamin C one among the antiadhesive agents. Moreover, Vitamin C has been found to exhibit chemotherapy properties against cancer and improved cancer patients' condition.…”

Section: Htr Cav and Ascorbic Acid (Asc)mentioning

confidence: 99%

See 3 more Smart Citations

Therapeutic potential role of vitamin C in prevention and control of heart transplant rejection and cardiac allograft vasculopathy. A need for consideration

Kenedy,

Kabuhaya,

Mashauri

2023

Health Science Reports

View full text Add to dashboard Cite

The burden of cardiovascular diseases is rising rapidly globally. Heart transplant is one of the most last resort medical option for patients with heart failure. Unfortunately, this surgical intervention is associated with several serious complications including heart transplant rejection (HTR) and Cardiac Allograft Vasculopathy (CAV) which can manifest just within few years' posttransplant. These complications affect significantly the prognosis and quality of life among postheart transplant patients. Several medications including immunosuppressant, antibiotics, antihypertensive, and statins have been used during posttransplant care so as to address such complications. Unfortunately, most of those drugs are expensive and pose a number of serious side effects to the patients enough to compromise patients' quality of life too. Several studies on Vitamin C are therapeutically suggestive that it can be used during postheart transplant care with more cost‐effective benefits with less and minimized side effects compared to the current drugs in place. It should be considered pharmacologically that Vitamin C has a great potential role clinically in prevention and control of HTR and CAV development. On the light of such findings as described above, we recommend more studies especially clinical trials and molecular studies to determine whether Vitamin C can be repositioned to replace or to be used along the current drug regimens used in postheart transplant care for prevention and control of HTR and CAV.

show abstract

Section: Discussionmentioning

confidence: 99%